Analytical Data
-
Gene name
TAL2
- Application
-
Alternative Names
TAL2; BHLHA19; T-cell acute lymphocytic leukemia protein 2; TAL-2; Class A basic helix-loop-helix protein 19; bHLHa19
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q16559
-
Expression Region
1-108 aa
-
AA Sequence
MTRKIFTNTR ERWRQQNVNS AFAKLRKLIP THPPDKKLSK NETLRLAMRY INFLVKVLGE QSLQQTGVAA QGNILGLFPQ GPHLPGLEDR TLLENYQVPS PGPSHHIP
-
Molecular Weight
12.2kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
TAL2, a member of the T-box transcription factor family, plays a crucial role in various biological processes, including embryonic development, cell differentiation, and the maintenance of stem cell properties. It is particularly significant in the context of hematopoiesis and neurogenesis, where its expression is tightly regulated. Abnormal regulation of TAL2 has been implicated in certain hematological malignancies, such as T-cell acute lymphoblastic leukemia (T-ALL). The study of TAL2 and its mechanisms of action is essential for understanding its role in development and disease. Researchers have been interested in exploring TAL2 as a potential therapeutic target, aiming to develop recombinant TAL2 proteins that can be used to investigate its functional properties in vitro and in vivo. This involves the production of recombinant TAL2 proteins to study their interactions with DNA and other proteins, as well as their effects on gene expression. The insights gained from these studies could pave the way for novel approaches in treating disorders associated with TAL2 dysregulation, offering promising avenues for future research in cancer therapeutics and regenerative medicine.
